StoxCohance Lifesciences vs Poly Medicure: share price & financials comparison
NSE: COHANCE vs POLYMED · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Cohance Lifesciences vs Poly Medicure at a glance
Cohance Lifesciences (COHANCE) has a market capitalisation of ₹16,588 Cr, against ₹16,342 Cr for Poly Medicure (POLYMED). Over the past year Poly Medicure has returned -18.1%, compared with -44.9% for Cohance Lifesciences. On valuation, Poly Medicure trades at a lower P/E of 51.3 versus 156.1. Poly Medicure earns a higher return on equity (9.8% vs 2.7%). Cohance Lifesciences comes out ahead on financial health and technicals. Poly Medicure comes out ahead on size, profitability, growth and momentum. Across the scored metrics below, Cohance Lifesciences leads on 3 and Poly Medicure on 13. On StoxGud's 10-point checklist, Cohance Lifesciences scores 3/10 and Poly Medicure scores 6/10.
| Metric | Cohance Lifesciences | Poly Medicure |
|---|---|---|
| Size | ||
| Market cap | ₹16,588 Cr | ₹16,342 Cr |
| Revenue (latest FY) | ₹2,269 Cr | ₹1,875 Cr |
| Net profit (latest FY) | ₹179 Cr | ₹322 Cr |
| Valuation | ||
| P/E | 156.1 | 51.3 |
| P/B | 4.24 | 5.00 |
| Dividend yield | — | 0.22% |
| Profitability | ||
| Return on equity | 2.7% | 9.8% |
| Net profit margin | 5.0% | 14.9% |
| Operating margin | 14.8% | 22.7% |
| Growth | ||
| Revenue growth (YoY) | -23.1% | +30.8% |
| Net profit growth (YoY) | -149.3% | +3.6% |
| Revenue CAGR (multi-year) | +18.2% | +19.0% |
| Financial health | ||
| Debt to equity | 0.04 | 0.12 |
| Momentum | ||
| 1-month return | -4.8% | -0.2% |
| 1-year return | -44.9% | -18.1% |
| 3-year CAGR | -8.8% | +5.5% |
| 5-year CAGR | -2.9% | +12.2% |
| 10-year CAGR | — | +23.6% |
| Distance from 52W high | -44.3% | -21.9% |
| Technicals | ||
| RSI (14) | 39 | 52 |
| Price vs 200-day avg | +5.9% | +4.3% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Cohance Lifesciences | Poly Medicure |
|---|---|---|
| Price above 50-day average | ✗ | ✗ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✓ |
| Positive 1-year return | ✗ | ✗ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✗ | ✓ |
| Net profit margin above 10% | ✗ | ✓ |
| P/E below industry median | ✗ | ✗ |
| Score | 3/10 | 6/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Cohance Lifesciences or Poly Medicure?
Cohance Lifesciences has a market cap of ₹16,588 Cr and Poly Medicure has a market cap of ₹16,342 Cr as of 06 Nov 2026.
Which has a lower P/E, Cohance Lifesciences or Poly Medicure?
Poly Medicure has the lower P/E: Cohance Lifesciences trades at 156.1 and Poly Medicure at 51.3.
Which gave better returns in the last year, Cohance Lifesciences or Poly Medicure?
Poly Medicure did better: Cohance Lifesciences returned -44.9% and Poly Medicure returned -18.1% over one year.
Is Cohance Lifesciences or Poly Medicure a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Cohance Lifesciences scores 3/10 and Poly Medicure scores 6/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.